Adverum Biotechnologies Reports First Quarter 2023 Financial Results
11 mai 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
- Full enrollment of the Phase 2 LUNA trial in wet age-related macular degeneration (wet AMD) is anticipated in the second half of 2023 - - LUNA 14-week data, including initial aflibercept protein...
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
10 mai 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD
02 mai 2023 16h30 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
23 avr. 2023 13h00 HE
|
Adverum Biotechnologies, Inc.
- Wet age-related macular degeneration (wet AMD) is a bilateral disease and incidence of neovascularization (nAMD) in the second eye is up to 42% in the first two to three years following diagnosis in...
Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD
18 avr. 2023 08h00 HE
|
Adverum Biotechnologies, Inc.
- Innovative Licensing and Access Pathway designation is intended to accelerate the regulatory review process in the United Kingdom - - Ixo-vec has also been granted Fast Track Designation by the...
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
17 avr. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
30 mars 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
- Full enrollment of the LUNA trial anticipated in the second half of 2023 - - LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023 - - LUNA...
Adverum Biotechnologies to Present at Upcoming Investor Conferences
27 févr. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 janv. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 déc. 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...